ClinConnect ClinConnect Logo
Search / Trial NCT01916980

Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)

Launched by ORGANON AND CO · Aug 2, 2013

Trial Information

Current as of July 23, 2025

Completed

Keywords

Dermatitis Dermatitis, Atopic Skin Diseases Skin Diseases, Genetic Genetic Diseases, Inborn Skin Diseases, Eczematous Hypersensitivity, Immediate Hypersensitivity Immune System Diseases

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Eczema/dermatitis (acute eczema, chronic eczema, contact dermatitis, atopic dermatitis, nummular eczema, seborrheic dermatitis, asteatotic eczema, neurodermatitis, etc. among eczema/dermatitis for which the observation of pruritus is appropriate)
  • Dermal pruritus (generalized dermal pruritus, localized dermal pruritus)
  • Exclusion Criteria:
  • Hypersensitivity to antihistamines or ingredients of a study drug

About Organon And Co

Organon & Co. is a global healthcare company dedicated to advancing women's health and improving patient outcomes through innovative therapies and solutions. With a strong focus on addressing unmet medical needs, Organon develops and commercializes a diverse portfolio of medicines, including reproductive health, contraception, and other critical areas affecting women's health. Committed to scientific excellence and collaboration, the company engages in clinical trials to explore new treatment avenues and enhance the quality of life for patients worldwide. Through its mission-driven approach, Organon strives to empower women and healthcare providers with the tools and resources necessary for informed decision-making and effective care.

Locations

Patients applied

0 patients applied

Trial Officials

Medical Director

Study Director

Merck Sharp & Dohme LLC

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials